All In Biotech

Drug Trial Radar · NCT05860465

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitor Combined With Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Sep 8, 2023

Primary completion

Dec 1, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • SPH4336 TabletsDrug

    SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion

  • SPH4336 Tablets PlaceboDrug

    SPH4336 Tablets Placebo :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: Approximately 3years
  2. Progression-free survival (PFS)Time frame: Approximately 3years

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, China · Recruiting

  • Shenzhen Hospital of University of Hong Kong

    Shenzhen, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Affiliated Cancer Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Liuzhou people's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • Anyang Cancer Hospital

    Anyang, He'nan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, He'nan, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Xiangyang Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China · Recruiting

  • The second people's hospital of neijiang

    Neijiang, Sichuan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • Zhejiang cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.